PharmAust Ltd
PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials… Read more
PharmAust Ltd (PAA) - Net Assets
Latest net assets as of June 2024: AU$10.23 Million AUD
Based on the latest financial reports, PharmAust Ltd (PAA) has net assets worth AU$10.23 Million AUD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$11.12 Million) and total liabilities (AU$896.61K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$10.23 Million |
| % of Total Assets | 91.94% |
| Annual Growth Rate | 4.15% |
| 5-Year Change | 19.96% |
| 10-Year Change | 15.72% |
| Growth Volatility | 498.45 |
PharmAust Ltd - Net Assets Trend (2001–2024)
This chart illustrates how PharmAust Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PharmAust Ltd (2001–2024)
The table below shows the annual net assets of PharmAust Ltd from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | AU$10.23 Million | +163.00% |
| 2023-06-30 | AU$3.89 Million | -50.42% |
| 2022-06-30 | AU$7.84 Million | -11.67% |
| 2021-06-30 | AU$8.88 Million | +4.15% |
| 2020-06-30 | AU$8.53 Million | +14.36% |
| 2019-06-30 | AU$7.46 Million | +4.45% |
| 2018-06-30 | AU$7.14 Million | +3.23% |
| 2017-06-30 | AU$6.92 Million | +37.66% |
| 2016-06-30 | AU$5.02 Million | -43.17% |
| 2015-06-30 | AU$8.84 Million | +13.27% |
| 2014-06-30 | AU$7.80 Million | +2410.21% |
| 2013-06-30 | AU$310.88K | -74.37% |
| 2012-06-30 | AU$1.21 Million | +5.65% |
| 2011-06-30 | AU$1.15 Million | -80.23% |
| 2010-06-30 | AU$5.81 Million | -0.84% |
| 2009-06-30 | AU$5.86 Million | -0.97% |
| 2008-06-30 | AU$5.91 Million | -24.52% |
| 2007-06-30 | AU$7.84 Million | +1.93% |
| 2006-06-30 | AU$7.69 Million | +98.70% |
| 2005-06-30 | AU$3.87 Million | +422.03% |
| 2004-06-30 | AU$741.02K | -59.15% |
| 2003-06-30 | AU$1.81 Million | -47.72% |
| 2002-06-30 | AU$3.47 Million | -13.47% |
| 2001-06-30 | AU$4.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmAust Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6203755800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$69.94 Million | 683.75% |
| Other Comprehensive Income | AU$4.42 Million | 43.26% |
| Total Equity | AU$10.23 Million | 100.00% |
PharmAust Ltd Competitors by Market Cap
The table below lists competitors of PharmAust Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arctic Fish Holding AS
OL:AFISH
|
$36.81 Million |
|
Capital & Regional Plc
PINK:CRPLF
|
$36.81 Million |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
$36.81 Million |
|
Singular Genomics Systems Inc
NASDAQ:OMIC
|
$36.81 Million |
|
Optomed PLC
HE:OPTOMED
|
$36.80 Million |
|
The Cato Corporation
F:CO2A
|
$36.80 Million |
|
Korea New Network Co. Ltd
KQ:058400
|
$36.78 Million |
|
TRJNF
PINK:TRJNF
|
$36.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmAust Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,889,135 to 10,228,243, a change of 6,339,108 (163.0%).
- Net loss of 9,032,356 reduced equity.
- New share issuances of 13,306,962 increased equity.
- Other comprehensive income increased equity by 1,709,331.
- Other factors increased equity by 355,171.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-9.03 Million | -88.31% |
| Share Issuances | AU$13.31 Million | +130.1% |
| Other Comprehensive Income | AU$1.71 Million | +16.71% |
| Other Changes | AU$355.17K | +3.47% |
| Total Change | AU$- | 163.00% |
Book Value vs Market Value Analysis
This analysis compares PharmAust Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.03x to 5.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-06-30 | AU$4.93 | AU$0.17 | x |
| 2002-06-30 | AU$3.22 | AU$0.17 | x |
| 2003-06-30 | AU$1.38 | AU$0.17 | x |
| 2004-06-30 | AU$0.35 | AU$0.17 | x |
| 2005-06-30 | AU$1.15 | AU$0.17 | x |
| 2006-06-30 | AU$1.69 | AU$0.17 | x |
| 2007-06-30 | AU$1.25 | AU$0.17 | x |
| 2008-06-30 | AU$0.49 | AU$0.17 | x |
| 2009-06-30 | AU$0.42 | AU$0.17 | x |
| 2010-06-30 | AU$0.40 | AU$0.17 | x |
| 2011-06-30 | AU$0.07 | AU$0.17 | x |
| 2012-06-30 | AU$0.05 | AU$0.17 | x |
| 2013-06-30 | AU$0.01 | AU$0.17 | x |
| 2014-06-30 | AU$0.12 | AU$0.17 | x |
| 2015-06-30 | AU$0.12 | AU$0.17 | x |
| 2016-06-30 | AU$0.05 | AU$0.17 | x |
| 2017-06-30 | AU$0.06 | AU$0.17 | x |
| 2018-06-30 | AU$0.05 | AU$0.17 | x |
| 2019-06-30 | AU$0.03 | AU$0.17 | x |
| 2020-06-30 | AU$0.03 | AU$0.17 | x |
| 2021-06-30 | AU$0.03 | AU$0.17 | x |
| 2022-06-30 | AU$0.02 | AU$0.17 | x |
| 2023-06-30 | AU$0.01 | AU$0.17 | x |
| 2024-06-30 | AU$0.03 | AU$0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmAust Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-88.31%) is below the historical average (-87.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -52.23% | 0.00% | 0.00x | 1.24x | AU$-2.50 Million |
| 2002 | -106.78% | -546.46% | 0.14x | 1.42x | AU$-4.05 Million |
| 2003 | -114.29% | -3050.03% | 0.03x | 1.39x | AU$-2.25 Million |
| 2004 | 5.59% | 12.03% | 0.34x | 1.37x | AU$-29.03K |
| 2005 | -86.95% | -104.76% | 0.61x | 1.36x | AU$-3.75 Million |
| 2006 | -35.81% | -45.08% | 0.67x | 1.19x | AU$-3.52 Million |
| 2007 | -83.92% | -92.20% | 0.70x | 1.30x | AU$-7.36 Million |
| 2008 | -97.53% | -206.40% | 0.35x | 1.35x | AU$-6.36 Million |
| 2009 | -3.07% | -10.23% | 0.23x | 1.29x | AU$-765.26K |
| 2010 | -7.55% | -26.73% | 0.24x | 1.18x | AU$-1.02 Million |
| 2011 | -505.10% | -373.46% | 1.07x | 1.26x | AU$-5.91 Million |
| 2012 | -351.30% | -263.34% | 0.67x | 1.99x | AU$-4.38 Million |
| 2013 | -165.62% | -30.11% | 1.89x | 2.91x | AU$-545.97K |
| 2014 | -16.97% | -67.95% | 0.24x | 1.06x | AU$-2.09 Million |
| 2015 | -21.78% | -81.18% | 0.25x | 1.08x | AU$-2.81 Million |
| 2016 | -78.18% | -144.50% | 0.43x | 1.25x | AU$-4.43 Million |
| 2017 | -19.43% | -40.62% | 0.40x | 1.19x | AU$-2.04 Million |
| 2018 | -35.33% | -77.38% | 0.39x | 1.17x | AU$-3.24 Million |
| 2019 | -20.81% | -35.69% | 0.51x | 1.15x | AU$-2.30 Million |
| 2020 | -15.97% | -42.62% | 0.30x | 1.26x | AU$-2.21 Million |
| 2021 | -15.06% | -62.48% | 0.20x | 1.23x | AU$-2.23 Million |
| 2022 | -21.78% | -50.52% | 0.34x | 1.28x | AU$-2.49 Million |
| 2023 | -159.72% | -219.96% | 0.46x | 1.58x | AU$-6.60 Million |
| 2024 | -88.31% | 0.00% | 0.00x | 1.09x | AU$-10.06 Million |
Industry Comparison
This section compares PharmAust Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $16,842,941
- Average return on equity (ROE) among peers: -39.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmAust Ltd (PAA) | AU$10.23 Million | -52.23% | 0.09x | $36.80 Million |
| Adalta Ltd (1AD) | $4.07 Million | -94.65% | 0.09x | $150.42K |
| Algorae Pharmaceuticals Ltd (1AI) | $6.76 Million | -100.52% | 0.11x | $9.99 Million |
| ACRUX Ltd (ACR) | $43.92 Million | -0.55% | 0.08x | $1.98 Million |
| Argenica Therapeutics Ltd (AGN) | $7.24 Million | -99.08% | 0.53x | $11.14 Million |
| Arovella Therapeutics Ltd (ALA) | $3.00 Million | -25.05% | 0.05x | $39.20 Million |
| Anatara Lifesciences Ltd (ANR) | $2.86 Million | -117.78% | 0.17x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $9.07 Million | -11.63% | 0.04x | $2.26 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $363.79 |
| Cambium Bio Ltd (CMB) | $8.10 Million | 40.38% | 0.13x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $72.07 Million | 23.10% | 0.13x | $244.42 Million |